Request Demo

Last update 15 Jul 2026

Modafinil

Last update 15 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryModafinil, a minuscule molecular compound marketed as PROVIGIL, received its initial approval in 1992. This drug is principally utilized to enhance vigilance among adult patients who are plagued by excessive sleepiness, a symptom of narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). However, it is important to note that PROVIGIL is not intended to treat the underlying causes of these sleep disorders; rather, its function is to heighten the patient's aptitude to remain alert during daylight hours. As a central nervous system stimulant, Modafinil operates by augmenting the activity of particular chemicals located within the brain that are implicated in regulating the sleep-wake cycle.

Drug Type

Small molecule drug

Synonyms

2-((diphenylmethyl)sulfinyl)acetamide, Alertec, Attenace

+ [25]

Target

DAT

Action

antagonists

Mechanism

DAT antagonists(Dopamine transporter antagonists)

Therapeutic Areas

Nervous System DiseasesRespiratory DiseasesOther Diseases

Active Indication

Idiopathic HypersomniaDisorders of Excessive SomnolenceNarcolepsy+ [3]

Inactive Indication

Alzheimer DiseaseApathyAttention Deficit Disorder With Hyperactivity+ [11]

Originator Organization

Teva Pharmaceuticals Europe BV

Active Organization

Tanabe Pharma Corp.

Teva Pharmaceutical Industries Ltd.Nuvo Pharmaceuticals (Ireland) DAC

+ [3]

Inactive Organization

Cephalon LLC

License Organization

Neuraxpharm

Drug Highest PhaseApproved

First Approval Date

United States (24 Dec 1998),

NarcolepsySleep Apnea, ObstructiveSleep Disorders, Circadian Rhythm+ [1]

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC15H15NO2S

InChIKeyYFGHCGITMMYXAQ-UHFFFAOYSA-N

CAS Registry68693-11-8

225

Clinical Trials associated with Modafinil

NCT07263022

/ Not yet recruitingPhase 3IIT

Cognitive Strategies in Early Psychosis 2

The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last five years. The investigators will study how two study agents change decision making in people with psychosis, by asking participants to complete some brain games on the computer before and after taking the study agents. The investigators hope to improve our understanding of psychosis to help people in the future. The main research questions are:
* Does a single dose of modafinil change how people with psychosis play the brain games?
* Does a single dose of d-serine change how people with psychosis play the brain games?
* Does a single dose of modafinil change brain activity?
* Does a single dose of d-serine change brain activity?
Participants will:
* Complete an interview and self-report questionnaires.
* Complete safety screening activities, like a blood draw, a urine drug test, and an alcohol breathalyzer test.
* Complete functional Magnetic Resonance Imaging (fMRI) scans. fMRI uses magnets to take pictures of the brain. There will be six scanning appointments in the study, with two scans each. Appointments will be about a month apart.
* Take a single dose of a study agent during each scanning appointment. The study agent will be taken after the first fMRI. There are three study agents in total: modafinil, d-serine, and a placebo. Each participant will take each study agent twice during the study.
* Play brain games on a computer that measure decision making, thinking, and problem solving skills

Start Date21 Jul 2026

Sponsor / Collaborator

University of Minnesota

[+1]

NCT07582458

/ Not yet recruitingPhase 2/3IIT

Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease: a Multicentre,Randomised, Double-blind, Placebo-controlled, Clinical Trial (MODIFI-IBD Trial)

The goal of this clinical trial is to learn if modafinil can treat severe fatigue in adults aged 18 to 75 years with quiescent inflammatory bowel disease (IBD). The main questions it aims to answer are:
Does modafinil reduce fatigue more effectively than placebo, as measured by the mean difference in section I of the IBD-F questionnaire at week 8? Is modafinil safe and well tolerated in patients with quiescent IBD and severe fatigue?
Researchers will compare modafinil to placebo to see if modafinil improves fatigue outcomes.
Participants will:
attend one screening visit including assessment of disease activity, blood tests, stool testing, and an ECG; take modafinil or placebo for 8 weeks, starting at 100 mg daily with possible dose increases based on response and tolerability; complete online questionnaires at baseline, week 4, week 8, and week 12 about fatigue, quality of life, sleep, mood, and work productivity; be contacted regularly during the treatment period to discuss effect and side effects of the study medication; complete an online effort-based decision-making task at baseline and week 8.

Start Date01 Jun 2026

Sponsor / Collaborator

Radboud University Medical Center

NCT07568574

/ Enrolling by invitationNot Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Objectives:
The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure period and 5 year long term follow-up of period comprehensive health and safety monitoring. The secondary objective is to evaluate the impact of PES on athletic performance through validated sport specific and clinical assessments.
Methods:
This prospective hybrid design study will enrol 60 adult participants, divided into two groups. The first group will receive performance-enhancing substances (PES) directly through the study, administered as Investigational Medicinal Products (IMPs) under comprehensive medical supervision for up to 25 weeks. The second group will include natural athletes and those already using PES prescribed by their own doctors. All substances used in this study are medically approved by national regulatory agencies (e.g., FDA, MHRA, EMA, EDE, etc.), and market authorised.
Participants undergo enrollment and baseline health and performance assessments, prior to a 25 weeks of PES exposure. During the period of PES exposure, participants undergo periodic monitoring of comprehensive physiological biomarkers alongside subjective assessments. Following the PES exposure phase, participants will complete repeat baseline health and performance assessments, followed by a titration phase and, where indicated, post-cycle therapy (PCT) to support the restoration of physiological function toward baseline. The study will conclude with a five-year longitudinal follow-up period to monitor long-term health outcomes. During this phase, participants will undergo annual assessments, including cardiac electrocardiography (ECG), echocardiography, magnetic resonance imaging (MRI), blood and urine biomarkers, routine vital signs, and quality-of-life measures. Additional imaging will include brain functional MRI (fMRI) and vital organ ultrasound at years 1, 3, and 5, with cardiac CT performed as clinically indicated. Athlete safety biomarker assessments, clinical evaluations, and adverse event reporting, will be continuously evaluated by study doctors and with additional safety oversight from a Data Safety Monitoring Board, Independent Medical Commission (a multidisciplinary panel of medical experts), and a Medical Monitor.

Start Date12 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Modafinil

100 Translational Medicine associated with Modafinil

100 Patents (Medical) associated with Modafinil

2,061

Literatures (Medical) associated with Modafinil

01 Dec 2026·Sleep medicine: X

An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy

Review

Author: Pakkam, Madona L ; Mann, Govind Singh ; Kukadiya, Romil ; Girigosavi, Khushal B ; Sufiyan, Nimra ; Ramakrishnan, Manju

Background:

Narcolepsy is a chronic disorder characterized by excessive daytime sleepiness (EDS) and cataplexy, often triggered by stress, sleep disturbances, pregnancy, or trauma. Modafinil is a preferred treatment for EDS, known for improving quality of life, though long-term safety and efficacy data remain limited. This review was registered with PROSPERO (CRD420251136771).

Aim:

This systematic review and meta-analysis evaluated the effectiveness of Modafinil in treating narcolepsy.

Methods:

A comprehensive search of databases (PubMed, Embase, Google Scholar, Scopus, ScienceDirect, Web of Science) was conducted to identify cohort studies and randomized controlled trials (RCTs) up to August 2025. Efficacy outcomes included the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS). Statistical analysis using Review Manager 5.4 compared Modafinil to placebo. The review aimed to reassess and synthesize existing randomized evidence rather than identify new efficacy trials.

Results:

Of 4567 articles screened, nine studies were included in the systematic review, and five studies, involving 997 adult patients, were analyzed in the meta-analysis. Modafinil significantly improved MWT scores (MD = 3.56, 95% CI [2.25-4.86]) and reduced ESS scores (MD = -3.34, 95% CI [-4.13 to -2.56]). Moderate heterogeneity was observed but was reduced following pre-specified sensitivity analyses.

Conclusion:

These findings confirm the short-term efficacy of modafinil in reducing excessive daytime sleepiness based on legacy randomized controlled trials conducted primarily in the 1990s and early 2000s, while highlighting the absence of new eligible RCTs in the past decade. However, long-term efficacy and safety remain to be established, underscoring the need for larger, long-duration randomized trials.

01 Dec 2026·Journal of Clinical Sleep Medicine

Real-world effectiveness and tolerability of wake-promoting agents for residual sleepiness in treated obstructive sleep apnea

Article

Author: Morgenthaler, Timothy I ; Auger, R Robert ; Seo, Heather ; Roberts, Jessica M

Residual sleepiness despite effective positive airway pressure (PAP) therapy remains a persistent clinical problem in obstructive sleep apnea (OSA). This retrospective study evaluated real-world use, effectiveness, and tolerability of modafinil, armodafinil, and solriamfetol in 50 adults with OSA and residual sleepiness. Most patients received modafinil (80%) as their initial agent. Complete, partial, and poor responses occurred in 26%, 44%, and 30% of patients, respectively. Adverse events were reported in 38%-predominantly neurologic and psychiatric-and led to discontinuation in ten cases. Response did not correlate with apnea severity, body mass index, or PAP adherence, and no single agent demonstrated superior benefit. These findings contrast with the stronger efficacy and tolerability reported in randomized controlled trials, underscoring the need for individualized therapy and realistic counseling about benefits and side effects when prescribing wake-promoting agents in clinical practice.

01 Jul 2026·PHYSIOLOGY & BEHAVIOR

Involvement of the α1-adrenergic receptor in caffeine-induced drug discrimination and conditioned taste avoidance in rats

Article

Author: Rauhut, Anthony S

The present experiments determined the role of the α₁-adrenergic receptor in mediating the behavioral actions of caffeine in rats utilizing two different paradigms: drug discrimination (DD) and conditioned taste avoidance (CTA). After rats achieved response proficiency (80% caffeine-appropriate responding) with caffeine (30 mg/kg) during DD training, rats underwent stimulus generalization tests in which rats were administered vehicle (0.5% gum Arabic) or modafinil (5, 10 or 20 mg/kg) 30 min prior to the session, as determined by a Latin-Square design. In the CTA experiment, two conditioning sessions occurred 48-h apart in which rats received 15 min access to salt water (0.6%) followed immediately by an injection of vehicle (distilled water) or prazosin (0.5, 1.0, or 2.0 mg/kg) and then 5 min later a second injection of vehicle (physiological saline) or caffeine (30 mg/kg). The test session occurred 96 h after the last conditioning session. The α₁-adrenergic agonist, modafinil, dose-dependently generalized to caffeine. The selective α₁-adrenergic antagonist, prazosin, dose-dependently potentiated caffeine-induced CTA. Taken together, these results suggest that the α₁-adrenergic receptor system contributes to the behavioral actions of a moderate caffeine dose.

News (Medical) associated with Modafinil

22 May 2026

·www.einpresswire.com

Demand for Narcolepsy Market is forecasted to reach a value of US $6.51 billion by 2030

The Business Research Company's Demand for Narcolepsy Market is forecasted to reach a value of US $6.51 billion by 2030 Expected to grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, May 21, 2026 / EINPresswire.com / -- "Narcolepsy market to surpass $7 billion in 2030. In comparison, the Sleeping Aids market, which is considered as its parent market, is expected to be approximately $136 billion by 2030, with Narcolepsy to represent around 5% of the parent market. Within the broader Pharmaceuticals industry, which is expected to be $2,496 billion by 2030, the Narcolepsy market is estimated to account for nearly 0.3% of the total market value. Which Will Be The Biggest Region In The Narcolepsy Market In 2030? North America will be the largest region in the narcolepsy market in 2030, valued at $2.4 billion. The market is expected to grow from $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The rapid growth can be attributed to increasing awareness and diagnosis of sleep disorders, strong presence of advanced healthcare infrastructure, rising healthcare expenditure, favorable reimbursement frameworks supporting treatment access, and growing availability of specialized sleep clinics and diagnostic centers across the USA and Canada. Which Will Be The Largest Country In The Global Narcolepsy Market In 2030? The USA will be the largest country in the narcolepsy market in 2030, valued at $2.1 billion. The market is expected to grow from $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The strong growth can be attributed to strong presence of leading pharmaceutical companies, rising investment in neurological and sleep disorder research, growing adoption of advanced therapeutics and novel drug formulations, increasing participation in clinical trials for sleep disorder treatments, and continuous innovation in treatment approaches and patient management solutions across the country. Request A Free Sample Of The Narcolepsy Market Report https://www.thebusinessresearchcompany.com/sample_request?id=16491&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=May_PR What Will Be The Largest Segment In The Narcolepsy Market In 2030? The narcolepsy market is segmented by type into type 1, and type 2. The type 1 market will be the largest segment of the narcolepsy market segmented by type, accounting for 57% or $4 billion of the total in 2030. The type 1 market will be supported by the increasing prevalence and diagnosis of narcolepsy with cataplexy, rising awareness of sleep disorders among patients and healthcare providers, growing adoption of advanced and targeted therapeutics, expanding research and development activities focused on neurological disorders, improving access to specialized sleep clinics and diagnostic tools, and supportive reimbursement policies facilitating long-term treatment adherence. The narcolepsy market is segmented by treatment into antidepressants, stimulants, sodium oxybate, and other treatments. The narcolepsy market is segmented by diagnosis into polysomnogram, and multiple sleep latency test. What Is The Expected CAGR For The Narcolepsy Market Leading Up To 2030? The expected CAGR for the narcolepsy market leading up to 2030 is 10%. What Will Be The Growth Driving Factors In The Global Narcolepsy Market In The Forecast Period? The rapid growth of the global narcolepsy market leading up to 2030 will be driven by the following key factors that are expected to increase awareness and diagnosis of narcolepsy, accelerate advancements in pharmacological treatment options, and support the growth of digital healthcare and telemedicine services for improved patient management. Increasing Awareness And Diagnosis Of Narcolepsy - The increasing awareness and diagnosis of narcolepsy is expected to become a key growth driver for the narcolepsy market by 2030. Rising awareness among healthcare professionals and the general population is significantly improving diagnosis rates of narcolepsy. Historically underdiagnosed, the condition is now being identified more accurately due to educational campaigns, improved diagnostic tools, and better clinical understanding. Early diagnosis increases demand for treatment options such as medications, behavioral therapy, and patient support programs. Healthcare providers are also more vigilant in identifying symptoms like excessive daytime sleepiness and cataplexy. This leads to earlier intervention and long-term disease management. As a result, the increasing awareness and diagnosis of narcolepsy is anticipated to contribute to 2.1% annual growth in the market. Advancements In Pharmacological Treatments - The advancements in pharmacological treatments is expected to emerge as a major factor driving the expansion of the narcolepsy market by 2030. Continuous advancements in drug development, including therapies such as pitolisant, modafinil, and armodafinil, are driving market growth. These medications offer improved efficacy, fewer side effects, and better patient adherence compared to older treatments. Pharmaceutical companies are investing in research and clinical trials to develop innovative therapies targeting sleep-wake regulation. Regulatory approvals are expanding access to these drugs across multiple regions. As treatment options improve, physicians are more likely to prescribe them, increasing adoption rates. Consequently, the advancement in pharmacological treatments is projected to contribute to around 1.9% annual growth in the market. Growth Of Digital Healthcare And Telemedicine Services - The growth of digital healthcare and telemedicine services is expected to act as a key growth catalyst for the narcolepsy market by 2030. The rapid adoption of telemedicine and digital healthcare platforms is improving access to narcolepsy care. Patients can consult specialists remotely, reducing geographical and logistical barriers. Telemedicine supports continuous monitoring and follow-up, which is essential for chronic conditions like narcolepsy. Digital tools such as sleep tracking applications and virtual therapy programs enhance patient engagement and adherence to treatment. This shift toward remote healthcare solutions is particularly beneficial in underserved areas. Therefore, the growth of digital healthcare and telemedicine services is projected to contribute to approximately 1.6% annual growth in the market. Access The Detailed Narcolepsy Market Report Here https://www.thebusinessresearchcompany.com/report/narcolepsy-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=May_PR What Are The Key Growth Opportunities In The Narcolepsy Market In 2030? The most significant growth opportunities are anticipated in the type 1 market, and the type 2 market. Collectively, these segments are projected to contribute over $2.5 billion in market value by 2030, driven by increasing awareness and diagnosis of sleep disorders, rising demand for effective and long-term treatment options, advancements in neurological research and drug development, growing adoption of innovative therapeutics and personalized treatment approaches, and improving access to specialized sleep clinics and diagnostic technologies. This surge reflects the accelerating focus on enhancing patient outcomes, improving quality of life, and supporting innovation in sleep disorder management, fuelling transformative growth within the broader neurological and sleep disorder therapeutics industry. The type 1 market is projected to grow by $1.4 billion, and the type 2 market by $1.1 billion over the next five years from 2025 to 2030. Learn More About The Business Research Company The Business Research Company ( www.thebusinessresearchcompany.com ) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more. Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance. Contact Us: The Business Research Company Americas +1 310-496-7795 Europe +44 7882 955267 Asia & Others +44 7882 955267 & +91 8897263534 Email: marketing@tbrc.info Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company " Oliver Guirdham The Business Research Company +44 7882 955267 info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

01 Apr 2026

·www.sciencedaily.com

Millions start work too early. This drug helps them stay awake

Millions of people start work before sunrise—but their brains aren’t ready for it. A new clinical trial has found that the wake-promoting drug solriamfetol can significantly boost alertness in early-morning shift workers struggling with shift work disorder. Participants who took the drug were able to stay awake and function better throughout full shifts, with improvements in productivity, safety, and daily performance.Far more people work very early morning shifts than overnight schedules, yet many struggle with severe fatigue linked to shift work disorder. This condition can interfere with concentration, job performance, and safety. A new clinical trial led by researchers at Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early morning shift workers stay more alert. The findings were published in NEJM Evidence. "Until now, no clinical trial had tested a treatment for shift work disorder in early-morning shift workers, even though this is the most common type of shift schedule," said senior author Charles A. Czeisler, PhD, MD, chief and senior physician of the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine. "This study addresses a major gap by focusing on the workers who start their day when most people are still asleep." Why Early Shifts Disrupt the Body's Clock Roughly one in four workers operates outside the standard 9 to 5 schedule, including those who begin work very early in the morning. Many people with these schedules do not consider themselves shift workers and instead see their routine as simply starting the day earlier than usual. However, they may still face a high risk of shift work disorder, which involves disrupted sleep patterns and persistent daytime sleepiness. "People who start work between 3 a.m. and 7 a.m. are waking up at a time when the brain is biologically programmed to sleep. That makes staying alert extraordinarily difficult, even when they are highly motivated," said first author Kirsi-Marja Zitting, PhD, an investigator with the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine. "They are often dealing with a double burden -- excessive sleepiness during work hours and difficulty sleeping enough when they have the chance to rest." Health and Safety Risks of Shift Work Disorder Shift work disorder is linked to a range of serious concerns, including reduced mental sharpness, lower productivity, increased risk of car accidents, and more workplace injuries. Medications such as modafinil are sometimes used to promote wakefulness, but these drugs have mainly been studied in overnight workers and can interfere with sleep later in the day. Solriamfetol, the drug evaluated in this study, is already approved for treating excessive sleepiness in people with obstructive sleep apnea and narcolepsy. Researchers considered it a promising option because it can promote alertness for extended periods without significantly disrupting later sleep. Clinical Trial Shows Improved Alertness and Performance The study included 78 early morning shift workers diagnosed with shift work disorder. Participants were randomly assigned to take either solriamfetol or a placebo on workdays over a four-week period. Researchers assessed their ability to stay awake in a controlled, low-stimulation setting during hours that matched their typical work schedule. Participants also reported on their daily functioning and met regularly with clinicians. After four weeks, those who received solriamfetol showed clear improvements. They were less sleepy and could remain awake longer during simulated work hours. Both participants and their doctors noted better overall functioning, improved work performance, and greater ability to manage daily tasks. "The improvement we saw is clinically meaningful. These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life," Czeisler said. "Shift workers are essential to how our society functions, yet they often pay a hidden biological cost. This study shows we can do better for them." More Research Needed on Long-Term Effects The researchers emphasized that early morning shift workers have not been widely studied, and the current trial lasted only four weeks and included otherwise healthy adults. More research will be needed to understand the long-term effects of the treatment. The team is now enrolling participants for a follow-up clinical trial to study solriamfetol in overnight shift workers, which could help support broader approval for treating shift work disorder. In addition to Zitting and Czeisler, Mass General Brigham authors include Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, and Jeanne F. Duffy. Additional authors include Eileen B. Leary. Funded by Jazz Pharmaceuticals, Axsome Therapeutics, and Brigham and Women's Hospital Center for Clinical Investigation; NCT04788953(2021-03-09)

Clinical ResultDrug Approval

26 Mar 2026

·www.prnewswire.com

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY

NUTLEY, N.J., March 26, 2026 /PRNewswire/ -- Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, dose escalation study in adult patients with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2). Three dose strengths of E2086 per NT1 or NT2 participants will be assessed compared with placebo using objective and patient-reported measures of wake promotion. Narcolepsy is a sleep disorder resulting from disorganization of the sleep/wakefulness cycle. In patients with NT1, excessive daytime sleepiness and cataplexy (acute episodes of loss of muscle tone) are reported in association with low levels of the neurotransmitter orexin. In patients with NT2, excessive daytime sleepiness occurs, but without reports of cataplexy. As a selective orexin-2 receptor agonist, E2086 is hypothesized to compensate for the loss of orexin in patients with narcolepsy. In nonclinical studies, E2086 was shown to increase wake time and decrease cataplexy-like episodes in narcolepsy model mice and to prolong wakefulness in wild-type mice.1 In a recently completed proof-of-mechanism study in patients with NT1, compared with placebo and an existing treatment (modafinil), E2086 provided statistically significant and clinically meaningful increases in wake time as assessed by the objective maintenance of wakefulness test and by the patient-reported Karolinska sleepiness scale.2 For information about this study, please contact Eisai Medical Information at or 1-888-274-2378 (Monday through Friday 8:30 AM – 5:00 PM EST, excluding holidays). About E2086 E2086 is Eisai's in-house discovered novel selective orexin 2 receptor agonist. Nonclinical studies have demonstrated statistically significant increases in time spent awake and significant reductions in rates of cataplexy. Individuals with a deficiency of orexin demonstrate excessive daytime sleepiness (EDS), as exemplified by patients with narcolepsy Type 1, demonstrate a loss of orexinergic neurons, and low cerebrospinal fluid (CSF) orexin levels. E2086 has the potential to improve patients' symptoms by enhancing orexin receptor activity. About Eisai Inc. Eisai Inc. is a human health care (hhc) company dedicated to improving the lives of people affected by cancer, Alzheimer's disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them. Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good. Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities. To learn more, please visit us at and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages. SOURCE Eisai Inc. 21% more press release views with Request a Demo

Phase 2

100 Deals associated with Modafinil

External Link

KEGG	Wiki	ATC	Drug Bank
D01832	Modafinil	N06BA07	DB00745

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Idiopathic Hypersomnia	Japan	Alfresa Pharma Corp.	21 Feb 2020
Disorders of Excessive Somnolence	Canada	Teva Pharmaceutical Industries Ltd.	24 Mar 1999
Narcolepsy	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleep Apnea, Obstructive	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleep Disorders, Circadian Rhythm	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleepiness	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	Cephalon LLC	01 Jul 2005
Apathy	Phase 3	United States	Cephalon LLC	01 Jul 2005
Cataplexy	Phase 3	United States	Cephalon LLC	01 Oct 2004
Cataplexy	Phase 3	Canada	Cephalon LLC	01 Oct 2004
Obstructive Sleep Apnea Hypopnea Syndrome	Phase 3	United States	Cephalon LLC	01 Oct 2004
Obstructive Sleep Apnea Hypopnea Syndrome	Phase 3	Canada	Cephalon LLC	01 Oct 2004
Attention Deficit Disorder With Hyperactivity	Phase 3	United States	Cephalon LLC	01 Sep 2003
Depressive Disorder, Major	Phase 3	-	Cephalon LLC	01 Feb 2003
Depressive Disorder	Phase 2	Germany	Cephalon LLC	01 May 2008
Sleep Deprivation	Phase 2	Germany	Cephalon LLC	01 May 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03772314 (Pubmed \| CNS Drugs) Manual	Phase 2	Narcolepsy \| Idiopathic Hypersomnia	-	Modafinil	ekafocqnpn(mgkvdhgwat) = nnqgtyktjq pbrsbkesrx (tpeejzpnws, 2.7) Not Met View more	Negative	21 Sep 2024
				Amphetamine-Dextroamphetamine	ekafocqnpn(mgkvdhgwat) = zocctzgzfa pbrsbkesrx (tpeejzpnws, 4.7) Not Met View more
NCT03621761 (COMBO-MS, ACTRIMS2023)	Phase 4	Multiple Sclerosis	336	Telephone-based Cognitive Behavioral Therapy (CBT)	bsmsbtaqkg(nbxdsoayzm) = yxegibbxfx kcjwnzojoh (lbdphehcab, 11.9)	Positive	30 May 2023
				Modafinil	bsmsbtaqkg(nbxdsoayzm) = emhgatvjps kcjwnzojoh (lbdphehcab, 15.9)
NCT03621761 (COMBO-MS, CTgov)	Phase 4	Fatigue \| Multiple Sclerosis	343	Telephone-based Cognitive Behavioral Therapy (Cognitive Behavioral Therapy)	nhcmrmbsnj(tgkfznbfwp) = dnxcyqepzq gltkinsukz (usbezgpoat, 11.9) View more	-	27 Dec 2022
				Modafinil (Modafinil)	nhcmrmbsnj(tgkfznbfwp) = bthfxrijaz gltkinsukz (usbezgpoat, 15.9) View more
NCT03083132 (CTgov)	Phase 2	Mental Fatigue \| Parkinson Disease	21	modafinil 50mg (Early-start)	donnfxcrsh(sntombikos) = aavocmruyf krwppunnsx (vtntdesfyp, 2.53) View more	-	27 Oct 2021
				Placebo oral capsule+modafinil 50mg (Delayed-start)	donnfxcrsh(sntombikos) = mygwwocetf krwppunnsx (vtntdesfyp, 1.62) View more
NCT01381718 (CTgov)	Phase 2	Cognition \| Neurotoxicity Syndromes \| Cognitive Dysfunction ... View more	112	Modafinil (Arm I - Modafinil)	fxfkdpejrt(nveutvadqs) = qezzvxmwra yrxsqzstge (nmqzjhzeaa, 0.71) View more	-	13 Aug 2021
				placebo (Arm II - Placebo)	fxfkdpejrt(nveutvadqs) = xhumujmxwv yrxsqzstge (nmqzjhzeaa, 1.06) View more
NCT03185065 (TRIUMPHANT-MS, CTgov)	Phase 3	Fatigue \| Multiple Sclerosis	141	placebo (Placebo)	optlawdmpz(xtbubvjwoi) = xwagtdikgt bvlmwftrwp (uxztclpadi, pigenchccb - qmdxcfjxgg) View more	-	19 Oct 2020
				Amantadine (Amantadine)	optlawdmpz(xtbubvjwoi) = eogodsuuqb bvlmwftrwp (uxztclpadi, ljujjevldz - pgtxsauaap) View more
NCT03424681 (CTgov)	Phase 2	Alcohol Use Disorder	12	Modafinil (Modafinil)	bfpewljotf(nqutunpicn) = fwfsptwuch wsizkclqfh (wozwonasiz, 27) View more	-	26 May 2020
				Placebo (Placebo)	bfpewljotf(nqutunpicn) = bmjavcgrph wsizkclqfh (wozwonasiz, 32) View more
NCT01913327 (APD, CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	4	Aripiprazole+Modafinil (Aripiprazole)	kmdomxcola(qpnjojipbq) = icybhijydz exhzghkvjs (akzjdepvrk, jvligyszgp - dikhtawzju) View more	-	20 Apr 2020
				risperidone+Modafinil (Risperidone)	kmdomxcola(qpnjojipbq) = dbiuqxpslp exhzghkvjs (akzjdepvrk, rxvyyszmyx - jwamwxkygc) View more
WSC2019	Not Applicable	Sleep Apnea, Obstructive	1,714	Solriamfetol 150 mg	jzxwbgelok(prkksvjdcv) = rnrbeuqmje gaqyrxvabl (iiykyvoios, 3% - 64%)	Positive	20 Sep 2019
NCT02494102 (ModOSA, CTgov)	Phase 4	Sleep Apnea, Obstructive \| Anesthesia \| Emergence Delirium	105	Placebo (Placebo)	cfeydhkrmg(lhikrdpoxj) = nfthiqpmou zeezzqinhm (udeuwlccpz, xjeirharge - wmssnzppcn) View more	-	20 Jun 2019
				Modafinil (Intervention)	pszzhjiwiq(rtqzdyabji) = lukwijhgtw wgzmruhleh (cvzlpvyuty, bayitjxaku - syhnizohou) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis